Ide Smets

Neurologist@ErasMS_Rdam. Past ECTRIMS Clinical Fellow at Barts-MS London. Mainly talking 🧠-sense!

[touchNEUROLOGY @touchNEUROLOGY]

@drruthdobson (UK) and @SmetsIde (The Netherlands) explore the practicalities of therapeutic sequencing options in MS.

Watch now: https://t.co/KBGQa0QtrE

#MedTwitter #Neurology #NeuroImmunology #MS #MultipleSclerosis #MedEd

[MSJ @MSJ_Research]

Controversy ⚖️
Pre-symptomatic #MultipleSclerosis or radiologically isolated syndrome #RIS should be actively monitored and treated.

🧵1/4

Link to commentary ▶️ https://t.co/1jwvc6HoQS

[Ide Smets @SmetsIde]

Not all MS drugs are created equal! In MS Center ErasMS gebruiken we daarom vanaf nu de Nederlandse versie van de #clinicspeak medicatie keuzetool. Vrij beschikbaar voor alle MS centra en pmMS. DM voor een visitekaartje! https://t.co/3o32TDKFP8

[Ide Smets @SmetsIde]

@PatriciaMunn604 @themsguide This is freely available on the https://t.co/rkMyvVuOFo website

[theMSguide.com 🧠 @themsguide]

This is a vastly improved tool to help make the best DMT choices.

https://t.co/6fClclrDGT

Question 2 is a real no-brainer!

Kudos to @SmetsIde

[Klaus Schmierer @KlausSchmierer]

Past & current #BartsMS @ectrims fellows @SmetsIde Drs Saul Reyes & Manuel Salavisa linking up with @preventiveneur1 senior lecturer @somehow_related at #ECTRIMS2022 @Iamsterdam

[Ide Smets @SmetsIde]

Very 🔥 debate with @XtineLebrunF and @drBWillekens on a late breaking topic: should we start treating radiologically isolated syndrome? A struggle between biology and disease, that needs to be addressed by new RIS criteria. @ECTRIMS

[Ide Smets @SmetsIde]

In simulated MS cohorts, lesion detection algorithms argue to be disease-modifying by detection more lesions, triggering early treatment switches and preventing disability. Nice feature or necessary add-on intervention?
https://t.co/bALFi2FIXr

[De Avondshow met Arjen Lubach @deavondshowvpro]

Russians: Do you want to join Holland?
(Namens Nederland, een referendum voor alle Russen: willen jullie bij Nederland horen?)

[Ide Smets @SmetsIde]

Rituximab (anti-CD20) is a more potent MS drug than dimethyl fumarate. The bigger question: is it better than the more costly ocrelizumab? Three possible answers: an official, a real and a right one. Which one do you prefer?@the_MSBlog https://t.co/juIWL45eWi

[Ide Smets @SmetsIde]

@MichaelRobersMD @ErasMS_Rdam Agree, it probably won’t be different for B cell tx, but my hope is we could evolve towards ‘focused retreatment’ with anti-CD20 based on a biomarker such as NfL

[Ide Smets @SmetsIde]

There’s no exit strategy for pwMS on anti-CD20 atm. Some argue there’s no need to exit, some argue to extend intervals and we argue to stop anti-CD20 after 4 infusion cycli. Do you agree? https://t.co/Jk4WLLv3sI @ErasMS_Rdam

[Ide Smets @SmetsIde]

The position of aHSCT in the MS treatment landscape is a source of debate, and for many pwMS it’s unclear who can benefit. In early aggressive MS it’s clear, but for progressive MS the risk/benefit profile of aHSCT shifts. @the_MSBlog https://t.co/i2No9H6KuK

[Ide Smets @SmetsIde]

During clincics, we are often too much focused on drugs, and forget to mention the second most-effective MS treatment: exercise. To compensate, I discuss my insights together with @themsguide in this podcast. #brainhealth
https://t.co/axuomUiIvl

[Ide Smets @SmetsIde]

Many pwMS need to gain a new expertise: overcoming administrative hurdles to gain access to crucial healthcare services such as rehab. In the UK this is the red tape, in the Netherlands a purple crocodile. Do you have any in your pool? https://t.co/HN6MmCYxC8 @ErasMS_Rdam

[theMSguide.com 🧠 @themsguide]

This is a superb post. I also struggle to understand why someone would fail to take the neurologist's advice. I guess @SmetsIde has put her finger on it when she suggests it may be a form of denial (my words).

MS is constantly vandalising our brains.

https://t.co/qG9uLU9wXn

[Ide Smets @SmetsIde]

Many pwMS struggle with DMT decisions when they have new lesions on brain MRI without new symptoms. Two attempts to better explain this clinical-MRI paradox: the topographical model of MS and road traffic. Do you stop for groceries at night? @the_MSBlog https://t.co/kg8kdMRdyb

[Ide Smets @SmetsIde]

@themsguide 💪🏻💪🏻

[Boaz Spermon @Boaz_Spermon]

Are the Dutch also ready to embrace HSCT as a first line treatment? @MSwebNL @msvereniging @MS_Research @NationalMSFonds @ErasMS_Rdam @Hersenbank @MScentrum020 @GTCumcg @nvneuropsy @SmetsIde @JeroenJGGeurts @HannekeHulst @Eef111 @NIN_knaw

[Ruth Dobson @drruthdobson]

A huge thanks to all the people with MS who helped us to design this leaflet for people with MS considering pregnancy https://t.co/QMrfQXUrvK. You had told us you wanted a reliable leaflet to be able to look at outside of clinic appointments that you could read in your own time.